Ming-chao L. Tsai
123 Ta Pei Road, Niao Sung 833
Kaohsiung, KHQ, Taiwan
Kaohsiung, KHQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications
Survival outcomes of conversion curative therapy following atezolizumab-bevacizumab in advanced hepatocellular carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: April 12, 2026
Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.
Journal: The Kaohsiung journal of medical sciences
Published: January 12, 2026
Concurrent Steatotic Liver Disease and Prognosis After Curative Resection of Hepatocellular Carcinoma.
Journal: Journal of hepatocellular carcinoma
Published: October 29, 2025
Pseudoprogression in Hepatocellular Carcinoma During Atezolizumab Plus Bevacizumab Therapy: A Case Report and a Review of Literature.
Journal: Cureus
Published: June 28, 2025
Delta-like 1 homologue (DLK1) predicts clinical outcomes in patients with hepatocellular carcinoma.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 23, 2025
Alternation of the oral, gastric and stool microbiome in patients with reflux esophagitis and Barrett's esophagus.
Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Published: March 16, 2025
Dynamic Muscle Atrophy Predicts Outcomes in Patients with Unresectable Hepatocellular Carcinoma Treated with First-Line Lenvatinib: A Retrospective Study in Taiwan.
Journal: Gut and liver
Published: February 09, 2025
Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.
Journal: American journal of cancer research
Published: September 28, 2024
Impact of concurrent MASLD on early-stage HCC following curative resection in chronic hepatitis B.
Journal: American journal of cancer research
Published: June 25, 2024
A new model based on preoperative AFP, albumin, and tumor burden score for predicting microvascular invasion in early-stage HCC.
Journal: American journal of cancer research
Published: June 21, 2024
Alternations of the gut microbiota and the Firmicutes/Bacteroidetes ratio after biologic treatment in inflammatory bowel disease.
Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Published: May 07, 2024
Last Updated: 09/26/2026